BRIEF published on 05/19/2026 at 07:05, 1 month 25 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 1 month 25 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
BRIEF published on 05/19/2026 at 07:05, 1 month 25 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 1 month 25 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
PRESS RELEASE published on 05/19/2026 at 07:00, 1 month 25 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
PRESS RELEASE published on 05/19/2026 at 07:00, 1 month 25 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
BRIEF published on 04/17/2026 at 21:05, 2 months 26 days ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 2 months 26 days ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 2 months 26 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 2 months 26 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 07/14/2026 at 01:45, 2 hours 38 minutes ago Arctic Fox Lithium Approved for Trading on the OTCQB Venture Market and Announces DTC Eligibility
Published on 07/14/2026 at 00:01, 4 hours 22 minutes ago Captor Capital Announces Delay in its Annual Filings
Published on 07/13/2026 at 23:10, 5 hours 13 minutes ago Galaxy Ventures Inc. Announces Director Resignation
Published on 07/13/2026 at 21:35, 6 hours 48 minutes ago ATHA Energy Announces Corporate Activities Update
Published on 07/13/2026 at 20:00, 8 hours 23 minutes ago IBC Announces Share-Based Compensation to Directors
Published on 07/13/2026 at 22:30, 5 hours 52 minutes ago Half-year 2026 Results Media and Investor Conference Call and Webcast
Published on 07/13/2026 at 21:20, 7 hours 2 minutes ago Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 21:17, 7 hours 5 minutes ago EQS-Adhoc: Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Published on 07/13/2026 at 20:48, 7 hours 34 minutes ago EQS-Adhoc: Gateway Real Estate AG: Forecast for the financial year 2026
Published on 07/13/2026 at 20:23, 7 hours 59 minutes ago EQS-Adhoc: TRATON SE: Preliminary operating result for Q2 2026 exceeds market expectations
Published on 07/13/2026 at 18:00, 10 hours 23 minutes ago CP Icade - Icade reprend 100% de la propriété de la Tour Eqho à la Défense
Published on 07/13/2026 at 18:00, 10 hours 23 minutes ago PR Icade - Icade regains full ownership of the Eqho Tower in La Défense
Published on 07/13/2026 at 18:00, 10 hours 23 minutes ago THERMADOR GROUPE : publication du chiffre d'affaires semestriel 2026
